Lifecore Biomedical
This article was originally published in The Gray Sheet
Executive Summary
Scuttled FDA General and Plastic Surgery Devices Panel review of the firm's Intergel anti-adhesion product will indirectly lead to a $0.09 per share loss in both the third and fourth quarter, company President and CEO Jim Bracke reports Feb. 2. The company had stocked sufficient amounts of the ferric hyaluronate-based product to accommodate an anticipated third quarter U.S. rollout, the exec explained. Addressing the panel recommendation against approval (1"The Gray Sheet" Jan. 17, p. 4), Bracke notes that panel members "were not given all information in advance," so they were unable to fairly evaluate the product. He adds that FDA has identified the additional data necessary to obtain approval and said that the agency "is not bound by the panel's recommendation." Bracke says he has "no idea" when the product could gain approval, however, analysts predict that Intergel gain market go-ahead in the next 6-12 months for use in reducing post-surgical adhesion formation after gynecological laparotomy procedures
You may also be interested in...
Data Deficiencies Derail Lifecore Intergel Liquid Adhesion Barrier PMA
Higher than expected infection rates, pending safety data and lingering questions over clinical efficacy prompted FDA's General and Plastic Surgery Devices Panel to recommend against approval of Lifecore Biomedical's Intergel adhesion prevention barrier solution in a 5-2 vote during a Jan. 12 meeting in Rockville, Maryland.
Aldeyra Hopes To Refile Dry Eye Drug Reproxalap Later In 2024
Following an FDA complete response letter last November, Aldeyra has agreed with the agency on a trial design to demonstrate efficacy in ocular discomfort, which the company can complete this year.
Colorado Price Cap Plan For Enbrel Draws Amgen Lawsuit; Cosentyx, Stelara ‘Affordability’ Reviews Pending
However, the state's recently formed prescription drug affordability board found Gilead’s Genvoya and Vertex’s Trikafta to be affordable.